MedTrace Logo

Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel

NCT04527211 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2020-08-26

No results posted yet for this study

Summary

It will be performed a randomized, multicenter, triple-masked, placebo-controlled clinical experiment to determine the effectiveness and safety of the administration to of ivermectin at a dose of 200 mcg/kg once a week for 7 weeks in a prophylactic treatment against SARS COV-2 infection in 550 Colombian health workers during the COVID-19 pandemic.

Conditions

  • Covid19
  • Healthcare Worker Patient Transmission

Interventions

DRUG

Ivermectin

Oral administration of ivermectin 200 mcg/kg every week for seven weeks

Sponsors & Collaborators

  • Javeriana University

    lead OTHER

Principal Investigators

  • Eduar D. Echeverri, Dr. · Pontificia Universidad Javeriana

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-07
Primary Completion
2020-11-30
Completion
2020-12-16

Countries

  • Colombia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04527211 on ClinicalTrials.gov